A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification

Completed · Phase 2 · Has a placebo group

Conditions studied: Aortic Valve Stenosis

In brief

The primary objective of the current study is to determine whether Ataciguat (HMR1766) slows progression of valve calcification in patients with moderate calcific aortic valve stenosis. Secondary and tertiary objectives are to determine whether Ataciguat slows progression of aortic valve function, reduces systemic inflammation, and prevents left ventricular dysfunction in patients with moderate calcific aortic valve stenosis.

Key facts

Study ID
NCT02481258
Run by
Mayo Clinic
People needed
35
Starts
2015-06-01
Expected to finish
2019-12-01
Last updated by the study team
2021-01-22

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.